TREVENA INC
TREVENA INC (TRVN): 3 pipeline candidates · ~10 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
9.5 months
D/E -1.82 · 0% dilution
Lead: Approved
3 candidates
N/A
N/A
A transparent, data-derived signal for TREVENA INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$10K
Cash
$14.1M
Quarterly Burn
$4.5M
Runway
9.5 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
Frequently asked questions
How many drug candidates are in TREVENA INC's pipeline?
TREVENA INC (TRVN) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is TREVENA INC's lead drug candidate?
TREVENA INC's most advanced tracked candidate is olinvyk (Approved) for management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate.
What is TREVENA INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, TREVENA INC has approximately 9.5 months of cash runway.
What is TREVENA INC's market capitalization?
TREVENA INC's market capitalization is approximately $10K.
Who is the CEO of TREVENA INC?
Ms. Carrie L. Bourdow is the chief executive officer of TREVENA INC (TRVN).
Get the full picture on TREVENA INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.